-
New Forum Software Installed (Still a few issues but reopening the forum) More details.
UK Royal College of Medicine: Long Covid webinar, 28 Sept 2023
- Thread starter Suffolkres
- Start date
Copy of details:
Spotlight on Long Covid: Part 3
About this event
At least 65 million individuals worldwide are estimated to have Long Covid, and more than 200 symptoms have been identified and attached to this often-debilitating illness*. Three years on from the start of the pandemic we continue to navigate and build our understanding of Long Covid’s impact, its best treatment pathways and question what the future holds.
Following on from our first two episodes in this series, we return to the topic with ‘Spotlight on Long Covid, part 3’. This extended webinar programme will present the most up-to-date knowledge of the condition, highlight findings from ongoing research and share key insights from clinicians, researchers and patients.
Joining us will be researchers from the LOCOMOTION study**, a £3.4 million project identifying the best ways to treat and support Long Covid, alongside clinicians who lead on the treatment, service development and our understanding of the long-term effects of COVID-19.
By attending this webinar, you will:
**
Long COVID Study (LOCOMOTION) is Optimising NHS Services (leeds.ac.uk)
Tickets
Standard pricing available until 27 September 2023.
Discounted tickets for patients and carers
If you are a patient/carer, please contact content@rsm.ac.uk for a discount code on our tickets
Spotlight on Long Covid: Part 3
About this event
- Date and timeThu 28 Sep 2023 from 12:00pm to 2:30pm
- LocationOnline
At least 65 million individuals worldwide are estimated to have Long Covid, and more than 200 symptoms have been identified and attached to this often-debilitating illness*. Three years on from the start of the pandemic we continue to navigate and build our understanding of Long Covid’s impact, its best treatment pathways and question what the future holds.
Following on from our first two episodes in this series, we return to the topic with ‘Spotlight on Long Covid, part 3’. This extended webinar programme will present the most up-to-date knowledge of the condition, highlight findings from ongoing research and share key insights from clinicians, researchers and patients.
Joining us will be researchers from the LOCOMOTION study**, a £3.4 million project identifying the best ways to treat and support Long Covid, alongside clinicians who lead on the treatment, service development and our understanding of the long-term effects of COVID-19.
By attending this webinar, you will:
- Receive an update on the latest statistics and research surrounding Long Covid
- Receive advice on how to manage and support patients with Long Covid
- Understand the treatment pathways currently available for those with Long Covid and how these pathways are resourced within the NHS
- Dive deeper into the key health topics within Long Covid, looking at symptoms, treatment, research and patient experience
**
Long COVID Study (LOCOMOTION) is Optimising NHS Services (leeds.ac.uk)
Tickets
Standard pricing available until 27 September 2023.
Discounted tickets for patients and carers
If you are a patient/carer, please contact content@rsm.ac.uk for a discount code on our tickets
rvallee
Senior Member (Voting Rights)
What treatment?! And best is being used very generously here. The least-worst-but-still-not-effective-at-all is not anyone's definition of best. Well, only in healthcare, I guess.
Although at least it's presenting the Patient-led paper (which was one of the top downloaded papers in Nature) and there is Brandan Delaney.
Greenhalgh, though...
There is mention of a C19-YRS symptom questionnaire. And wow is the site a self-promotion campaign of its own. Never heard of it, but they seem to think it's super important. Or something. The site has NICE's seal at the bottom.
It's a very standard questionnaire. Nothing special: https://c19-yrs.com/wp-content/uploads/2022/06/Modified-C19YRS_13_07_21-1.pdf. So much marketing in medicine... Hypedy hype and more hype.
Last edited:
